Skip to main content

Big news from china on the holidays

Big news from china this holiday will definitely be weighting on markets this monday.

#China’s official manufacturing #PMI fell to 50.8 in Sep, vs expected 51.2, previous 51.3.
The caixin manufacturing PMI, more closely tracking small private manufacturers, fell to 50, new low in 16 months, vs expected 50.5, previous 50.6

#BREAKING:
#PBOC cut #RRR for banks by 1%, effective from 15 Oct.
It will release about 1.2tn yuan liquidity, including 450bn yuan to be used to repay MLF coming due on 15 Oct.

AUD/USD might gap down on this news.

Labels:

Popular posts from this blog

5 crypto Investments that will make you a fortune

After 3 month of research based on business model analysis , technical analysis , market sentiment and market trends , I have reached to a decision of making a portfolio of 5 crypto currencies that have a big potential during the next period. It is expected that initial investment will almost have 4x return atleast , which means if you invest 10k , you will have a potential of reaching 50k atleast , there are 2 tokens out of the 5 tokens have a potential for almost 25x return on initial investment. The coins belong to projects from 4 different industries, they are issued by very succesful companies and supported by famouse blockchain creators and advisors.  I will help you create a profitable portfolio and follow up on these investments with weekly updates which will guide you to make the right entry and exit points. Feel free to contact me anytime on twitter @b4borio or email me at boriology@gmail.com
Post a Comment
Read more

GBP/USD rejected by trendline

The Pair rallied on Friday till it got rejected by trend-line on below chart on the 4h time-frame. it is recommended to sell the pair on testing the trendline, if broken , you should be on the buyers side till 1.2430-60 area . It is recommended to go long as well if the pair managed to retest the 1.2290 area which will be an area of  intraday support for the pair .
Read more

neximmune tatgeting 75$

NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the body’s own T cells to generate an immune response that mimics natural biology #nexi is up by 165% today.
Read more